Cited by 120Prostate Cancer Treatment and ResearchSteroid Chemistry and BiochemistryUrinary Bladder and Prostate Research

Identification of the Major Oxidative 3α-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5α-Androstane-3α,17β-diol to 5α-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease

Open access
Bauman, David R., Steckelbroeck, Stephan, Williams, Michelle V., Peehl, Donna M., Penning, Trevor M.·2006·Molecular Endocrinology

Abstract

Androgen-dependent prostate diseases initially require 5alpha-dihydrotestosterone (DHT) for growth. The DHT product 5alpha-androstane-3alpha,17beta-diol (3alpha-diol), is inactive at the androgen receptor (AR), but induces prostate growth, suggesting that an oxidative 3alpha-hydroxysteroid dehydrogenase (HSD) exists. Candidate enzymes that posses 3alpha-HSD activity are type 3 3alpha-HSD (AKR1C2), 11-cis retinol dehydrogenase (RODH 5), L-3-hydroxyacyl coenzyme A dehydrogenase , RODH like 3alpha-HSD (RL-HSD), novel type of human microsomal 3alpha-HSD, and retinol dehydrogenase 4 (RODH 4). In mammalian transfection studies all enzymes except AKR1C2 oxidized 3alpha-diol back to DHT where RODH 5, RODH 4, and RL-HSD were the most efficient. AKR1C2 catalyzed the reduction of DHT to 3alpha-diol, suggesting that its role is to eliminate DHT. Steady-state kinetic parameters indicated that RODH 4 and RL-HSD were high-affinity, low-capacity enzymes whereas RODH 5 was a low-affinity, high-capacity enzyme. AR-dependent reporter gene assays showed that RL-HSD, RODH 5, and RODH 4 shifted the dose-response curve for 3alpha-diol a 100-fold, yielding EC(50) values of 2.5 x 10(-9) M, 1.5 x 10(-9) M, and 1.0 x 10(-9) M, respectively, when compared with the empty vector (EC(50) = 1.9 x 10(-7) M). Real-time RT-PCR indicated that L-3-hydroxyacyl coenzyme A dehydrogenase and RL-HSD were expressed more than 15-fold higher compared with the other candidate oxidative enzymes in human prostate and that RL-HSD and AR were colocalized in primary prostate stromal cells. The data show that the major oxidative 3alpha-HSD in normal human prostate is RL-HSD and may be a new therapeutic target for treating prostate diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/me.2005-0287

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Handelsman DJ 2001 Androgen action and pharmaco- logic uses. In: DeGroot LJ, Jameson JL, Burger H, eds. Endocrinology. 4th ed. Philadelphia: W.B. Saunders Co; 2232-2242

Cited by

Sorted by citations

Authors
Bauman, D. R., Steckelbroeck, S., Williams, M. V., Peehl, D. M., & Penning, T. M.
Affiliations
  • University of Pennsylvania (US)
  • Stanford Medicine (US)
Corresponding author
Penning, Trevor M.
Venue
Molecular Endocrinology
Published
2006-02-01
Volume
20
Issue
2
Pages
444-458
ISSN
  • 0888-8809 (ISSN-L)
  • 1944-9917
OpenAlex
W2069335278
Cited by
120
References
59
Citations by year
2026: 3 · 2025: 3 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 6 · 2019: 9 · 2018: 4 · 2017: 5 · 2016: 7 · 2015: 6 · 2014: 9 · 2013: 12 · 2012: 6
FWCI
4.00
Type
journal article
Language
en
Open access
Locations
  • Molecular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense
  • University of Pennsylvania
  • National Institutes of Health
  • National Cancer Institute (R01 CA 90744, 1R25-CA-10187-D1, R01CA090744)
  • National Institute of Environmental Health Sciences (P30ES013508)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Steroid Chemistry and Biochemistry
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
Keywords
dihydrotestosterone, 5α-androstane-3α,17β-diol, 3alpha-diol, androgen receptor, prostate stromal cells, AKR1C2, enzyme kinetics, therapeutic target, enzyme colocalization
MeSH terms
Androgens, Animals, Cells, Cultured, Humans, Male, NADH, NADPH Oxidoreductases, Prostate, Prostatic Diseases, Receptors, Androgen, Dihydrotestosterone, Transfection, Androstane-3,17-diol, Transcriptional Activation, 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific), Fatty Acid Synthases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review